Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis
- J Microbiol. 2017 Jun;55(6):483-487. doi: 10.1007/s12275-017-6630-1.
- 1. Molecular Mechanisms of Antibiotics, Division of Life Science, Gyeongsang National University, Jinju, 52828, Republic of Korea.
- 2. Research Institute of Life Sciences, Gyeongsang National University, Jinju, 52828, Republic of Korea.
- 3. Interdisciplinary Program of Biomodulation, College of Natural Science, Myongji University, Yongin, 17058, Republic of Korea.
- 4. Myongji Bioefficiency Research Centre, Myongji University, Yongin, 17058, Republic of Korea.
- 5. Center for Nutraceutical and Pharmaceutical Materials, Myongji University, Yongin, 17058, Republic of Korea.
- 6. Department of Materials Science and Engineering, Northwestern University, Evanston, IL, 60208, USA.
- 7. Korean Institute of Tuberculosis, Osong, 28158, Republic of Korea.
- 8. Korean Institute of Tuberculosis, Osong, 28158, Republic of Korea. [email protected].
- 9. Korean National Tuberculosis Association, Seoul, 06763, Republic of Korea. [email protected].
This study aimed to provide information that bedaquilline is significantly effective for treatment of totally drug resistant (TDR) Mycobacterium tuberculosis that shows resistant to all first- and second-line drugs-using an innovative disc Agarose channel (DAC) system. Time-lapse images of single Bacterial cells under culture conditions with different concentrations of bedaquiline were analysed by image processing software to determine minimum inhibitory concentrations (MICs). Bedaquiline inhibited the growth of TDR M. tuberculosis strains, with MIC values ranging from 0.125 to 0.5 mg/L. The results of the present study demonstrate that bedaquiline, newly approved by the United States Food and Drug Administration (FDA), may offer therapeutic solutions for TDR-TB.